Posted on

Supplementary MaterialsFigure 1source data 1: Source data Figure 1

Supplementary MaterialsFigure 1source data 1: Source data Figure 1. Figure 7figure supplement 1. elife-59686-fig7-figsupp1-data1.xlsx (984K) GUID:?75FDFCF4-5EDF-4AA0-B10E-AC09C590187A Source data 1: Source data RNAseq_HCT116_HCT116 NCLX KO. elife-59686-data1.xlsx (1003K) GUID:?4EDB87E9-D64A-4902-BA33-1795558FA5B2 Transparent reporting form. elife-59686-transrepform.docx (246K) GUID:?6E817A3F-A17C-4E9A-BBF1-C33F70B82196 Data Availability StatementNo large data sets have been generated from the current study. All data generated or analysed during this study are included in the manuscript and supporting files. Source data files for all figures and figure supplements have been provided in Source data 1. Abstract Despite the established role of mitochondria in cancer, the mechanisms by which mitochondrial Ca2+ (mtCa2+) regulates tumorigenesis remain incompletely understood. The crucial role of mtCa2+ in tumorigenesis is highlighted by altered expression of proteins mediating mtCa2+ uptake and extrusion in cancer. Here, we demonstrate decreased expression of the mitochondrial Na+/Ca2+/Li+ exchanger NCLX (mRNA in colorectal tumor samples isolated from patients undergoing surgery at Penn State University Medical Center as compared to the paired normal adjacent tissues (Figure 1B). There was no difference in mRNA was appreciably reduced in CRC patients of all age groups (Figure 1figure supplement 1B). Both adenocarcinoma and mucinous adenocarcinoma had a significant reduction in mRNA levels as compared to the normal tissue (Figure 1figure supplement 1C). Subsequent analysis revealed a significant loss of NCLX in adenomas with malignant transformation from stage I through stage IV (Figure 1E). There was a significant reduction in mRNA level in late-stage (stage III and IV) colorectal tumors as compared to early-stage (stages I and Talarozole R enantiomer II) tumors from the TCGA database (Figure 1E,F), with similar results when we analyzed the patient samples obtained from Penn State University Medical Center (Figure 1G). Together, these results show that NCLX expression is significantly downregulated in CRC specimens, and that NCLX loss correlates with late-stage colorectal adenocarcinomas. Open in a separate window Figure 1. The Talarozole R enantiomer expression of NCLX, a mtCa2+ extrusion mediator in CRC cells, is decreased in CRC tumor samples from human patients.(A) TCGA data analysis showing mRNA levels in tumor tissues and adjacent normal tissues of COADREAD (colon and rectal adenocarcinoma) patients. Each data point represents an individual sample. (B) RT-qPCR analysis of mRNA in tumor tissues (n?=?30) and adjacent normal tissues (n?=?30) of CRC patients from Penn State University FACC Hospital. (C, D) TCGA data analysis showing mRNA level Talarozole R enantiomer in patients with and without KRAS, PI3K, (C) TP53, and BRAF (D) mutation. (ECF) TCGA data analysis showing NCLX mRNA in tumors at different cancer stages (stages ICIV) (E) or combined stage I/II (early stage) and stage III/IV (late-stage) (F) of COADREAD tissues compared to adjacent normal tissues. NA?=?stage not known (G) RT-qPCR analysis of mRNA in combined stage I/II (n?=?9) and stage III/IV (n?=?20) CRC tumor samples compared to their adjacent normal tissues obtained from Penn State University hospital. (H) Schematic representation of the colitis-associated regimen of AOM and DSS treatment. (ICK) Five representative colons from each experimental group are shown (I), quantification of the number of tumors (J), and tumor volume (K) in NCLX KO and control littermate mice at day 78 after AOM/DSS treatment. The red arrow indicates polyps in the colon and the white star represents fat tissue; n??30 mice per group. (L, M) Three replicates of representative H and E staining of colon sections where black arrows indicate dysplasia (scale bar 500 m) (L), histology score of dysplasia (scale bar 500 m) (M). Kruskal-Wallis ANOVA was performed to test single variables between the two groups. *p 0.05, **p 0.01, and ***p 0.001. Figure 1source data 1.Source data Figure 1.Click here to view.(10K, xlsx) Figure 1figure supplement 1. Open in a separate window Loss of NCLX reduces tumor number and size in the colitis-associated cancer model.(A) TCGA data analysis showing mRNA levels in tumors of male and female COADREAD patients. (B, C) TCGA data analysis showing a comparison of mRNA levels in COAD patients based.